Source disclosure: February 13, 2026
Cuorips Inc. [4894.T]
TOKYO, Feb 13 (Pulse News Wire) – Cuorips Inc. (4894.T) announced that its human induced pluripotent stem cell-derived cardiac muscle sheet product, IPSOC-1, will undergo a crucial regulatory review on February 19.
The Ministry of Health, Labour and Welfare has scheduled the meeting of the Pharmaceuticals and Medical Devices Agency's Regenerative Medicine Committee to discuss the approval status of IPSOC-1, which was submitted for manufacturing and sales authorization in April 2025. During the upcoming session, the committee will deliberate on whether to approve IPSOC-1 for treating severe heart failure caused by insufficient drug treatments or invasive procedures for ischemic cardiomyopathy.
The product has been designated as a regenerative medical product for rare diseases since October 24, 2025, under the designation number (R7)37. Cuorips stated that while the outcome of this meeting is unlikely to significantly impact the current fiscal period’s consolidated performance, the company will promptly disclose any important developments arising from the proceedings.
AI-translated content. 🟢 Confidence: High See terms • Original filing